Metabolon to Support National Large Cohort Studies
Metabolon, Inc., announced that it is expanding its efforts to apply metabolomics to large population health studies taking place around the world. To support this, the Company has grown its team to include Alex Forrest-Hay as Vice President of Population Health and his staff to exclusively focus on these initiatives. Prior to joining Metabolon, he was Director of Business Development at Affymetrix.
“Alex is a valuable addition to Metabolon because he has such a deep understanding of the goals of these large cohort studies and trusted relationships with population health thought leaders,” said Metabolon CEO John Ryals, PhD. “He and his team will help researchers maximize the value of combining genomics and metabolomics to identify disease risk factors and targets for preventive health care.”
Population health explores the health of large groups of people over time to better understand the underlying nature of wellness and disease. Programs are underway in the U.S., U.K., China and many other countries to collect genetic and biological samples and a wide variety of health information. This data will become a powerful resource in discovering why some people develop certain diseases and others do not.
“Genetic and environmental factors influencing health exert their effects by altering metabolite levels,” said Forrest-Hay. “As millions of patient samples are collected in these global studies, Metabolon’s technology will provide valuable, integrative knowledge toward understanding gene function and metabolic health. The Population Health team will work with leading government and academic researchers to establish Metabolon as the preferred provider of metabolomics data for these large-scale, multi-omic initiatives. These exciting programs are laying the foundations for using precision medicine in clinical practice, and metabolomics data will be essential for making this a reality.”
While genomics is viewed as a key component to precision medicine, there remains a need to understand additional factors, beyond one’s genes, to accurately reflect the current health status of an individual. The evolution of precision medicine benefits from research about broader population health. Overall, a better understanding of how all these factors work together may help improve the prevention, diagnosis and treatment of a wide range of chronic and life-threatening illnesses.
This article has been republished from materials provided by Metabolon. Note: material may have been edited for length and content. For further information, please contact the cited source.
Thermo and Biognosys Announce Co-Marketing AgreementNews
Partnership to provide a comprehensive, efficient workflow to enable library creation and data processing for Data-Independent Acquisition (DIA) studies.READ MORE
Salivary Biomarkers Could Aid Earlier Diagnosis of Alzheimer's DiseaseNews
Investigators at the Beaumont Research Institute are hopeful that their study involving small molecules in saliva will help identify those at risk of developing Alzheimer’s disease.READ MORE
Fat Metabolism in Live Fish: Real-Time Lipid Biochemistry ObservedNews
Using an HPLC-CAD/fluorescence lipidomics platform researchers have visualized and measured lipids in real time as they are metabolized by living fish.READ MORE
Comments | 0 ADD COMMENT
Next-Generation Antibodies and Protein Analysis (2nd Edition)
Oct 16 - Oct 17, 2017